Correlation Between Mineralys Therapeutics, and Opthea

Can any of the company-specific risk be diversified away by investing in both Mineralys Therapeutics, and Opthea at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mineralys Therapeutics, and Opthea into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mineralys Therapeutics, Common and Opthea, you can compare the effects of market volatilities on Mineralys Therapeutics, and Opthea and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mineralys Therapeutics, with a short position of Opthea. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mineralys Therapeutics, and Opthea.

Diversification Opportunities for Mineralys Therapeutics, and Opthea

0.72

Correlation Coefficient

Mineralys Therapeutics,  Opthea

Poor diversification

The 3 months correlation between Mineralys and Opthea is 0.72. Overlapping area represents the amount of risk that can be diversified away by holding Mineralys Therapeutics, Common and Opthea in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Opthea and Mineralys Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mineralys Therapeutics, Common are associated (or correlated) with Opthea. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Opthea has no effect on the direction of Mineralys Therapeutics, i.e., Mineralys Therapeutics, and Opthea go up and down completely randomly.

Pair Corralation between Mineralys Therapeutics, and Opthea

Given the investment horizon of 90 days Mineralys Therapeutics, is expected to generate 2.71 times less return on investment than Opthea. But when comparing it to its historical volatility, Mineralys Therapeutics, Common is 1.19 times less risky than Opthea. It trades about 0.05 of its potential returns per unit of risk. Opthea is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  291.00  in Opthea on September 2, 2024 and sell it today you would earn a total of  78.00  from holding Opthea or generate 26.8% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Mineralys Therapeutics, Common  vs.  Opthea

Mineralys Therapeutics,

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Opthea

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Opthea are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Opthea unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Mineralys Therapeutics, and Opthea

The main advantage of trading using opposite Mineralys Therapeutics, and Opthea positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mineralys Therapeutics, position performs unexpectedly, Opthea can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Opthea will offset losses from the drop in Opthea's long position.

The idea behind Mineralys Therapeutics, Common and Opthea pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.